[1] |
YUAN D P, LONG J, LU Y, et al. The forecast of anticancer targets of cryptotanshinone based on reverse pharmacophore-based screening technology[J]. Chin J Nat Med,2014,12(6):443-448. |
[2] |
CHEN L, ZHENG S Z, SUN Z G, et al. Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity[J]. Cancer Chemother Pharmacol,2011,68(1):17-27. doi: 10.1007/s00280-010-1440-8 |
[3] |
PARK I J, YANG W K, NAM S H, et al. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma[J]. Apoptosis,2014,19(4):615-628. doi: 10.1007/s10495-013-0929-0 |
[4] |
JI Y B, LIU Y C, XUE N N, et al. Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation[J]. Onco Targets Ther,2019,12:883-896. doi: 10.2147/OTT.S187777 |
[5] |
WU Y H, WU Y R, LI B, et al. Cryptotanshinone: a review of its pharmacology activities and molecular mechanisms[J]. Fitoterapia,2020,145:104633. doi: 10.1016/j.fitote.2020.104633 |
[6] |
LI H Y, GAO C D, LIU C, et al. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen[J]. Biomed Pharmacother,2021,137:111332. doi: 10.1016/j.biopha.2021.111332 |
[7] |
JIANG G Q, LIU J, REN B Y, et al. Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro[J]. J Ethnopharmacol,2017,205:33-40. doi: 10.1016/j.jep.2017.04.026 |
[8] |
MAN Y H, YANG L, ZHANG D X, et al. Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway[J]. Oncol Lett,2016,12(5):4094-4098. doi: 10.3892/ol.2016.5123 |
[9] |
LIU S, HAN Z, TRIVETT A L, et al. Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma[J]. Cancer Immunol Immunother,2019,68(7):1059-1071. doi: 10.1007/s00262-019-02326-8 |
[10] |
HAN Z, LIU S, LIN H S, et al. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses[J]. Cancer Immunol Immunother,2019,68(7):1073-1085. doi: 10.1007/s00262-019-02338-4 |
[11] |
DONG B W, LIANG Z R, CHEN Z R, et al. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation[J]. Sci China Life Sci,2018,61(9):999-1009. doi: 10.1007/s11427-018-9324-y |
[12] |
XIA C, BAI X P, HOU X Y, et al. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 pathway[J]. Cell Physiol Biochem,2015,37(2):816-824. doi: 10.1159/000430398 |
[13] |
HU T, TO K K, WANG L, et al. Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of Salvia miltior-rhiza[J]. Phytomedicine,2014,21(11):1264-1272. doi: 10.1016/j.phymed.2014.06.013 |
[14] |
WANG Y, LU H L, LIU Y D, et al. Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway[J]. Biomed Pharmacother,2017,95:1388-1396. doi: 10.1016/j.biopha.2017.09.062 |
[15] |
XU Z Y, JIANG H, ZHU Y H, et al. Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells[J]. Chem Biol Interact,2017,273:48-55. doi: 10.1016/j.cbi.2017.06.003 |
[16] |
HAO W H, ZHANG X N, ZHAO W W, et al. Cryptotanshinone induces pro-death autophagy through JNK signaling mediated by reactive oxygen species generation in lung cancer cells[J]. Anticancer Agents Med Chem,2016,16(5):593-600. doi: 10.2174/1871520615666150907093036 |
[17] |
ZOU S L, TONG Q Y, LIU B W, et al. Targeting STAT3 in cancer immunotherapy[J]. Mol Cancer,2020,19(1):145. doi: 10.1186/s12943-020-01258-7 |
[18] |
SHIN D S, KIM H N, SHIN K D, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells[J]. Cancer Res,2009,69(1):193-202. doi: 10.1158/0008-5472.CAN-08-2575 |
[19] |
CHEN L D, LV D Y, CHEN X F, et al. Biosensor-based active ingredients recognition system for screening STAT3 ligands from medical herbs[J]. Anal Chem,2018,90(15):8936-8945. doi: 10.1021/acs.analchem.8b01103 |
[20] |
BLASIUS R, REUTER S, HENRY E, et al. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells[J]. Biochem Pharmacol,2006,72(11):1547-1554. doi: 10.1016/j.bcp.2006.07.029 |
[21] |
GE Y Q, YANG B, CHEN Z, et al. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway[J]. Mol Med Rep,2015,12(5):7782-7788. doi: 10.3892/mmr.2015.4379 |
[22] |
YANG Y F, CAO Y, CHEN L H, et al. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells[J]. Cancer Med,2018,7(9):4610-4618. doi: 10.1002/cam4.1691 |
[23] |
YUAN X R, BU H, ZHOU J P, et al. Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application[J]. J Med Chem,2020,63(20):11368-11396. doi: 10.1021/acs.jmedchem.0c00249 |
[24] |
YU B, LIU W, YU W M, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies[J]. Mol Cancer Ther,2013,12(9):1738-1748. doi: 10.1158/1535-7163.MCT-13-0049-T |
[25] |
LIU W, YU B, XU G, et al. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)[J]. J Med Chem,2013,56(18):7212-7221. doi: 10.1021/jm400474r |
[26] |
LU L, ZHANG S L, LI C X, et al. Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation[J]. Cell Death Dis,2017,8(5):e2767. doi: 10.1038/cddis.2017.174 |
[27] |
HECK M M, EARNSHAW W C. Topoisomerase II: a specific marker for cell proliferation[J]. J Cell Biol,1986,103(6):2569-2581. doi: 10.1083/jcb.103.6.2569 |
[28] |
KIM E J, KIM S Y, KIM S M, et al. A novel topoisomerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity[J]. Toxicol Appl Pharmacol,2017,330:84-92. doi: 10.1016/j.taap.2017.07.007 |
[29] |
MOLONEY J N, COTTER T G. ROS signalling in the biology of cancer[J]. Semin Cell Dev Biol,2018,80:50-64. doi: 10.1016/j.semcdb.2017.05.023 |
[30] |
LIU C, SUN H N, LUO Y H, et al. Cryptotanshinone induces ROS-mediated apoptosis in human gastric cancer cells[J]. Oncotarget,2017,8(70):115398-115412. doi: 10.18632/oncotarget.23267 |
[31] |
YE T H, ZHU S R, ZHU Y X, et al. Cryptotanshinone induces melanoma cancer cells apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion[J]. Biomed Pharmacother,2016,82:319-326. doi: 10.1016/j.biopha.2016.05.015 |
[32] |
CHEN W X, LIU L, LUO Y, et al. Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells[J]. Cancer Prev Res (Phila),2012,5(5):778-787. doi: 10.1158/1940-6207.CAPR-11-0551 |
[33] |
PARK I J, KIM M J, PARK O J, et al. Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells[J]. Apoptosis,2012,17(3):248-257. doi: 10.1007/s10495-011-0680-3 |
[34] |
WU C Y, HSIEH C Y, HUANG K E, et al. Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function[J]. Int J Cancer,2012,131(6):1423-1434. doi: 10.1002/ijc.27343 |
[35] |
XU D F, LIN T H, LI S S, et al. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells[J]. Cancer Lett,2012,316(1):11-22. doi: 10.1016/j.canlet.2011.10.006 |
[36] |
PAN Y H, SHI J F, NI W T, et al. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer[J]. J Cell Mol Med,2017,21(9):2129-2139. doi: 10.1111/jcmm.13135 |
[37] |
LI S H, WANG H T, HONG L, et al. Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling[J]. Cancer Biol Ther,2015,16(1):176-184. doi: 10.4161/15384047.2014.962960 |
[38] |
KIM S A, KANG O H, KWON D Y. Cryptotanshinone induces cell cycle arrest and apoptosis of NSCLC cells through the PI3K/Akt/GSK-3β pathway[J]. Int J Mol Sci,2018,19(9):2739. doi: 10.3390/ijms19092739 |
[39] |
YE Y T, ZHONG W, SUN P, et al. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway[J]. J Ethnopharmacol,2017,200:107-116. doi: 10.1016/j.jep.2016.12.051 |
[40] |
ZHANG J T, WEN G L, SUN L H, et al. Cryptotanshinone inhibits cellular proliferation of human lung cancer cells through downregulation ofIGF-1R/PI3K/Akt signaling pathway[J]. Oncol Rep,2018,40(5):2926-2934. |
[41] |
ZHANG L, CHEN C, DUANMU J X, et a. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation[J]. Int Immunopharmacol,2018,65:429-437. doi: 10.1016/j.intimp.2018.10.035 |
[42] |
KE F Y, WANG Z, SONG X L, et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells[J]. Drug Des Devel Ther,2017,11:1753-1766. doi: 10.2147/DDDT.S132488 |
[43] |
ZHANG J, HUANG M, GUAN S, et al. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza[J]. J Pharmacol Exp Ther,2006,317(3):1285-1294. doi: 10.1124/jpet.105.100701 |
[44] |
刘航. 隐丹参酮衍生物的设计, 合成及其对STAT3转录活性的影响[D]. 福州: 福建中医药大学, 2021. |
[45] |
WANG H, LIU Z, GUAN L N, et al. LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppres-ses colorectal cancer growth and metastasis[J]. Pharmacol Res,2020,153:104661. doi: 10.1016/j.phrs.2020.104661 |
[46] |
XU D F, LIN T H, ZHANG C X, et al. The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells[J]. Prostate,2012,72(7):803-816. doi: 10.1002/pros.21474 |